Zobrazeno 1 - 10
of 13
pro vyhledávání: '"Hoefsmit EP"'
Autor:
Versluis JM; Department of Medical Oncology, Netherlands Cancer Institute, Amsterdam, The Netherlands., Hoefsmit EP; Division of Molecular Oncology & Immunology, Netherlands Cancer Institute, Amsterdam, The Netherlands., Shehwana H; Division of Molecular Oncology & Immunology, Netherlands Cancer Institute, Amsterdam, The Netherlands., Dimitriadis P; Division of Molecular Oncology & Immunology, Netherlands Cancer Institute, Amsterdam, The Netherlands., Sanders J; Department of Pathology, Netherlands Cancer Institute, Amsterdam, The Netherlands., Broeks A; Core Facility Molecular Pathology and Biobanking, Netherlands Cancer Institute, Amsterdam, The Netherlands., Blank CU; Department of Medical Oncology, Netherlands Cancer Institute, Amsterdam, The Netherlands. c.blank@nki.nl.; Division of Molecular Oncology & Immunology, Netherlands Cancer Institute, Amsterdam, The Netherlands. c.blank@nki.nl.; Department of Medical Oncology, Leiden University Medical Center, Leiden, The Netherlands. c.blank@nki.nl.
Publikováno v:
Cancer immunology, immunotherapy : CII [Cancer Immunol Immunother] 2024 Jan 27; Vol. 73 (2), pp. 28. Date of Electronic Publication: 2024 Jan 27.
Autor:
Schmitt C; Department of Dermatology and Allergy, University Hospital, LMU Munich, Munich, Germany., Hoefsmit EP; Department of Molecular Oncology and Immunology, Netherlands Cancer Institute, Amsterdam, The Netherlands., Fangmeier T; Department of Dermatology and Allergy, University Hospital, LMU Munich, Munich, Germany., Kramer N; Department of Dermatology and Allergy, University Hospital, LMU Munich, Munich, Germany., Kabakci C; Department of Dermatology and Allergy, University Hospital, LMU Munich, Munich, Germany., Vera González J; Department of Dermatology, Uniklinikum Erlangen and Friedrich-Alexander-Universität (FAU) Erlangen-Nürnberg, Erlangen, Germany., Versluis JM; Department of Medical Oncology, Netherlands Cancer Institute, Amsterdam, The Netherlands., Compter A; Department of Neuro-Oncology, Netherlands Cancer Institute, Amsterdam, The Netherlands., Harrer T; Department of Internal Medicine 3, Infectious Diseases and Immunodeficiency Section, Universitätsklinikum Erlangen, Friedrich-Alexander-Universität Erlangen-Nürnberg, Erlangen, Germany.; Deutsches Zentrum Für Immuntherapie (DZI), Friedrich-Alexander-Universität Erlangen-Nürnberg (FAU) and Universitätsklinikum Erlangen, Erlangen, Germany., Mijočević H; Max Von Pettenkofer Institute of Hygiene and Medical Microbiology, Faculty of Medicine, LMU Munich, Munich, Germany., Schubert S; Max Von Pettenkofer Institute of Hygiene and Medical Microbiology, Faculty of Medicine, LMU Munich, Munich, Germany., Hundsberger T; Departments of Neurology and Medical Oncology/Haematology, Cantonal Hospital, St. Gallen, Switzerland., Menzies AM; Melanoma Institute of Australia, The University of Sydney, Sydney, NSW, Australia.; Faculty of Medicine and Health, The University of Sydney, Sydney, NSW, Australia.; Department of Medical Oncology, Royal North Shore and Mater Hospitals, Sydney, NSW, Australia., Scolyer RA; Melanoma Institute of Australia, The University of Sydney, Sydney, NSW, Australia.; Faculty of Medicine and Health, The University of Sydney, Sydney, NSW, Australia.; Charles Perkins Centre, The University of Sydney, Sydney, NSW, Australia.; Tissue Pathology and Diagnostic Oncology, Royal Prince Alfred Hospital and NSW Health Pathology, Sydney, NSW, Australia., Long GV; Melanoma Institute of Australia, The University of Sydney, Sydney, NSW, Australia.; Faculty of Medicine and Health, The University of Sydney, Sydney, NSW, Australia.; Department of Medical Oncology, Royal North Shore and Mater Hospitals, Sydney, NSW, Australia.; Charles Perkins Centre, The University of Sydney, Sydney, NSW, Australia., French LE; Department of Dermatology and Allergy, University Hospital, LMU Munich, Munich, Germany.; Dr. Philip Frost, Department of Dermatology and Cutaneous Surgery, University of Miami Miller School of Medicine, Miami, FL, USA., Blank CU; Department of Molecular Oncology and Immunology, Netherlands Cancer Institute, Amsterdam, The Netherlands.; Department of Medical Oncology, Netherlands Cancer Institute, Amsterdam, The Netherlands.; Department of Medical Oncology, Leiden University Medical Center, Leiden, The Netherlands., Heinzerling LM; Department of Dermatology and Allergy, University Hospital, LMU Munich, Munich, Germany. Lucie.Heinzerling@med.uni-muenchen.de.; Department of Dermatology, Uniklinikum Erlangen and Friedrich-Alexander-Universität (FAU) Erlangen-Nürnberg, Erlangen, Germany. Lucie.Heinzerling@med.uni-muenchen.de.
Publikováno v:
Cancer immunology, immunotherapy : CII [Cancer Immunol Immunother] 2023 Nov; Vol. 72 (11), pp. 3475-3489. Date of Electronic Publication: 2023 Aug 22.
Autor:
Rozeman EA; Department of Medical Oncology, Netherlands Cancer Institute, Amsterdam, The Netherlands., Versluis JM; Department of Medical Oncology, Netherlands Cancer Institute, Amsterdam, The Netherlands., Sikorska K; Department of Biometrics, Netherlands Cancer Institute, Amsterdam, The Netherlands., Hoefsmit EP; Division of Molecular Oncology and Immunology, Netherlands Cancer Institute, Amsterdam, The Netherlands., Dimitriadis P; Division of Molecular Oncology and Immunology, Netherlands Cancer Institute, Amsterdam, The Netherlands., Rao D; Division of Molecular Oncology and Immunology, Netherlands Cancer Institute, Amsterdam, The Netherlands., Lacroix R; Division of Molecular Oncology and Immunology, Netherlands Cancer Institute, Amsterdam, The Netherlands., Grijpink-Ongering LG; Department of Biometrics, Netherlands Cancer Institute, Amsterdam, The Netherlands., Lopez-Yurda M; Department of Biometrics, Netherlands Cancer Institute, Amsterdam, The Netherlands., Heeres BC; Department of Radiology, Netherlands Cancer Institute, Amsterdam, The Netherlands., van de Wiel BA; Department of Pathology, Netherlands Cancer Institute, Amsterdam, The Netherlands., Flohil C; Department of Pathology, Netherlands Cancer Institute, Amsterdam, The Netherlands., Sari A; Department of Biometrics, Netherlands Cancer Institute, Amsterdam, The Netherlands., Heijmink SWTPJ; Department of Radiology, Netherlands Cancer Institute, Amsterdam, The Netherlands., van den Broek D; Department of Laboratory Medicine, Netherlands Cancer Institute, Amsterdam, The Netherlands., Broeks A; Core Facility and Biobanking, Netherlands Cancer Institute, Amsterdam, The Netherlands., de Groot JWB; Isala Oncology Center, Isala, Zwolle, The Netherlands., Vollebergh MA; Department of Medical Oncology, Netherlands Cancer Institute, Amsterdam, The Netherlands., Wilgenhof S; Department of Medical Oncology, Netherlands Cancer Institute, Amsterdam, The Netherlands., van Thienen JV; Department of Medical Oncology, Netherlands Cancer Institute, Amsterdam, The Netherlands., Haanen JBAG; Department of Medical Oncology, Netherlands Cancer Institute, Amsterdam, The Netherlands., Blank CU; Department of Medical Oncology, Netherlands Cancer Institute, Amsterdam, The Netherlands c.blank@nki.nl.; Division of Molecular Oncology and Immunology, Netherlands Cancer Institute, Amsterdam, The Netherlands.; Department of Medical Oncology, Leiden University Medical center, Leiden, The Netherlands.
Publikováno v:
Journal for immunotherapy of cancer [J Immunother Cancer] 2023 Jul; Vol. 11 (7).
Autor:
Rao D; Department of Molecular Oncology and Immunology, Netherlands Cancer Institute, Amsterdam, The Netherlands., Stunnenberg JA; Department of Molecular Oncology and Immunology, Netherlands Cancer Institute, Amsterdam, The Netherlands., Lacroix R; Department of Molecular Oncology and Immunology, Netherlands Cancer Institute, Amsterdam, The Netherlands., Dimitriadis P; Department of Molecular Oncology and Immunology, Netherlands Cancer Institute, Amsterdam, The Netherlands., Kaplon J; Department of Clinical Chemistry, Netherlands Cancer Institute, Amsterdam, The Netherlands., Verburg F; Department of Molecular Oncology and Immunology, Netherlands Cancer Institute, Amsterdam, The Netherlands., van van Royen PT; Department of Molecular Oncology and Immunology, Netherlands Cancer Institute, Amsterdam, The Netherlands., Hoefsmit EP; Department of Molecular Oncology and Immunology, Netherlands Cancer Institute, Amsterdam, The Netherlands., Renner K; Department of Internal Medicine III, Hematology and Medical Oncology, University Hospital Regensburg, Regensburg, Germany.; Department of Otorhinolaryngology, University Hospital Regensburg, Regensburg, Germany., Blank CU; Department of Molecular Oncology and Immunology, Netherlands Cancer Institute, Amsterdam, The Netherlands.; Department of Medical Oncology, Netherlands Cancer Institute, Amsterdam, The Netherlands.; Department of Internal Medicine, Leiden University Medical Center, Leiden, The Netherlands., Peeper DS; Department of Molecular Oncology and Immunology, Netherlands Cancer Institute, Amsterdam, The Netherlands.; Oncode Institute, The Netherlands.
Publikováno v:
European journal of immunology [Eur J Immunol] 2023 Jun; Vol. 53 (6), pp. e2250258. Date of Electronic Publication: 2023 Mar 19.
Autor:
Hoefsmit EP; Department of Molecular Oncology and Immunology, Netherlands Cancer Institute, Amsterdam, the Netherlands., Völlmy F; Biomolecular Mass Spectrometry and Proteomics, Center for Biomolecular Research and Utrecht Institute for Pharmaceutical Sciences, Utrecht University, Utrecht, the Netherlands., Rozeman EA; Department of Medical Oncology, Netherlands Cancer Institute, Amsterdam, the Netherlands., Reijers ILM; Department of Medical Oncology, Netherlands Cancer Institute, Amsterdam, the Netherlands., Versluis JM; Department of Medical Oncology, Netherlands Cancer Institute, Amsterdam, the Netherlands., Hoekman L; Proteomics Facility, Netherlands Cancer Institute, Amsterdam, the Netherlands., van Akkooi ACJ; Melanoma Institute Australia, The University of Sydney, Sydney, New South Wales, Australia.; Faculty of Medicine and Health, The University of Sydney, Sydney, New South Wales, Australia.; Department of Melanoma and Surgical Oncology, Royal Prince Alfred Hospital, Sydney, New South Wales, Australia., Long GV; Melanoma Institute Australia, The University of Sydney, Sydney, New South Wales, Australia.; Faculty of Medicine and Health, The University of Sydney, Sydney, New South Wales, Australia.; Charles Perkins Centre, The University of Sydney, Sydney, New South Wales, Australia.; Department of Medical Oncology, Royal North Shore and Mater Hospitals, Sydney, New South Wales, Australia., Schadendorf D; Department of Dermatology, University Hospital Essen and Germany Cancer Consortium, Partner Site Essen, Essen, Germany., Dummer R; Department of Dermatology, University Hospital Zürich, University Zürich, Zürich, Switzerland., Altelaar M; Biomolecular Mass Spectrometry and Proteomics, Center for Biomolecular Research and Utrecht Institute for Pharmaceutical Sciences, Utrecht University, Utrecht, the Netherlands.; Proteomics Facility, Netherlands Cancer Institute, Amsterdam, the Netherlands., Blank CU; Department of Molecular Oncology and Immunology, Netherlands Cancer Institute, Amsterdam, the Netherlands.; Department of Medical Oncology, Netherlands Cancer Institute, Amsterdam, the Netherlands.; Department of Medical Oncology, Leiden University Medical Center, Leiden, the Netherlands.
Publikováno v:
Cancer research communications [Cancer Res Commun] 2023 Apr 20; Vol. 3 (4), pp. 672-683. Date of Electronic Publication: 2023 Apr 20 (Print Publication: 2023).
Autor:
Hoefsmit EP; Department of Molecular Oncology and Immunology, Netherlands Cancer Institute, Amsterdam, the Netherlands., van Royen PT; Department of Molecular Oncology and Immunology, Netherlands Cancer Institute, Amsterdam, the Netherlands., Rao D; Department of Molecular Oncology and Immunology, Netherlands Cancer Institute, Amsterdam, the Netherlands., Stunnenberg JA; Department of Molecular Oncology and Immunology, Netherlands Cancer Institute, Amsterdam, the Netherlands., Dimitriadis P; Department of Molecular Oncology and Immunology, Netherlands Cancer Institute, Amsterdam, the Netherlands., Lieftink C; Robotics and Screening Facility, Netherlands Cancer Institute, Amsterdam, the Netherlands., Morris B; Robotics and Screening Facility, Netherlands Cancer Institute, Amsterdam, the Netherlands., Rozeman EA; Department of Medical Oncology, Netherlands Cancer Institute, Amsterdam, the Netherlands., Reijers ILM; Department of Medical Oncology, Netherlands Cancer Institute, Amsterdam, the Netherlands., Lacroix R; Department of Molecular Oncology and Immunology, Netherlands Cancer Institute, Amsterdam, the Netherlands., Shehwana H; Department of Molecular Oncology and Immunology, Netherlands Cancer Institute, Amsterdam, the Netherlands., Ligtenberg MA; Department of Molecular Oncology and Immunology, Netherlands Cancer Institute, Amsterdam, the Netherlands., Beijersbergen RL; Robotics and Screening Facility, Netherlands Cancer Institute, Amsterdam, the Netherlands.; Oncode Institute, the Netherlands., Peeper DS; Department of Molecular Oncology and Immunology, Netherlands Cancer Institute, Amsterdam, the Netherlands.; Oncode Institute, the Netherlands., Blank CU; Department of Molecular Oncology and Immunology, Netherlands Cancer Institute, Amsterdam, the Netherlands.; Department of Medical Oncology, Netherlands Cancer Institute, Amsterdam, the Netherlands.; Department of Internal Medicine, Leiden University Medical Center, Leiden, the Netherlands.
Publikováno v:
Cancer immunology research [Cancer Immunol Res] 2023 Apr 03; Vol. 11 (4), pp. 450-465.
Autor:
Fessenden TB; Koch Institute for Integrative Cancer Research at MIT, Massachusetts Institute of Technology, Cambridge, Massachusetts, USA., Stopfer LE; Koch Institute for Integrative Cancer Research at MIT, Massachusetts Institute of Technology, Cambridge, Massachusetts, USA.; Department of Biological Engineering, Massachusetts Institute of Technology, Cambridge, Massachusetts, USA., Chatterjee F; Koch Institute for Integrative Cancer Research at MIT, Massachusetts Institute of Technology, Cambridge, Massachusetts, USA.; Department of Biology, Massachusetts Institute of Technology, Cambridge, Massachusetts, USA., Zulueta J; Koch Institute for Integrative Cancer Research at MIT, Massachusetts Institute of Technology, Cambridge, Massachusetts, USA., Mesfin J; Department of Biological Engineering, Massachusetts Institute of Technology, Cambridge, Massachusetts, USA., Cordero Dumit T; Koch Institute for Integrative Cancer Research at MIT, Massachusetts Institute of Technology, Cambridge, Massachusetts, USA.; Department of Immunobiology, Yale University School of Medicine, New Haven, Connecticut, USA., Reijers I; Department of Medical Oncology, Netherlands Cancer Institute, Amsterdam, The Netherlands., Hoefsmit EP; Department of Molecular Oncology and Immunology, Netherlands Cancer Institute, Amsterdam, The Netherlands., Blank C; Department of Medical Oncology, Netherlands Cancer Institute, Amsterdam, The Netherlands.; Department of Molecular Oncology and Immunology, Netherlands Cancer Institute, Amsterdam, The Netherlands., White F; Koch Institute for Integrative Cancer Research at MIT, Massachusetts Institute of Technology, Cambridge, Massachusetts, USA.; Department of Biological Engineering, Massachusetts Institute of Technology, Cambridge, Massachusetts, USA., Spranger S; Koch Institute for Integrative Cancer Research at MIT, Massachusetts Institute of Technology, Cambridge, Massachusetts, USA spranger@mit.edu.; Department of Biology, Massachusetts Institute of Technology, Cambridge, Massachusetts, USA.; Ragon Institute of MGH, MIT and Harvard, Cambridge, Massachusetts, USA.
Publikováno v:
Journal for immunotherapy of cancer [J Immunother Cancer] 2022 Jul; Vol. 10 (7).
Autor:
Zhang Z; Division of Molecular Oncology and Immunology, Oncode Institute, the Netherlands Cancer Institute, Plesmanlaan 121, 1066 CX Amsterdam, the Netherlands., Kong X; Division of Molecular Oncology and Immunology, Oncode Institute, the Netherlands Cancer Institute, Plesmanlaan 121, 1066 CX Amsterdam, the Netherlands., Ligtenberg MA; Division of Molecular Oncology and Immunology, Oncode Institute, the Netherlands Cancer Institute, Plesmanlaan 121, 1066 CX Amsterdam, the Netherlands., van Hal-van Veen SE; Division of Molecular Oncology and Immunology, Oncode Institute, the Netherlands Cancer Institute, Plesmanlaan 121, 1066 CX Amsterdam, the Netherlands., Visser NL; Division of Molecular Oncology and Immunology, Oncode Institute, the Netherlands Cancer Institute, Plesmanlaan 121, 1066 CX Amsterdam, the Netherlands., de Bruijn B; Division of Molecular Oncology and Immunology, Oncode Institute, the Netherlands Cancer Institute, Plesmanlaan 121, 1066 CX Amsterdam, the Netherlands., Stecker K; Biomolecular Mass Spectrometry and Proteomics, Bijvoet Center for Biomolecular Research and Utrecht Institute for Pharmaceutical Sciences, University of Utrecht, and Netherlands Proteomics Center, Padualaan 8, 3584 CH Utrecht, the Netherlands., van der Helm PW; Division of Molecular Oncology and Immunology, Oncode Institute, the Netherlands Cancer Institute, Plesmanlaan 121, 1066 CX Amsterdam, the Netherlands., Kuilman T; Division of Molecular Oncology and Immunology, Oncode Institute, the Netherlands Cancer Institute, Plesmanlaan 121, 1066 CX Amsterdam, the Netherlands., Hoefsmit EP; Division of Molecular Oncology and Immunology, Oncode Institute, the Netherlands Cancer Institute, Plesmanlaan 121, 1066 CX Amsterdam, the Netherlands., Vredevoogd DW; Division of Molecular Oncology and Immunology, Oncode Institute, the Netherlands Cancer Institute, Plesmanlaan 121, 1066 CX Amsterdam, the Netherlands., Apriamashvili G; Division of Molecular Oncology and Immunology, Oncode Institute, the Netherlands Cancer Institute, Plesmanlaan 121, 1066 CX Amsterdam, the Netherlands., Baars B; Division of Molecular Oncology and Immunology, Oncode Institute, the Netherlands Cancer Institute, Plesmanlaan 121, 1066 CX Amsterdam, the Netherlands., Voest EE; Division of Molecular Oncology and Immunology, Oncode Institute, the Netherlands Cancer Institute, Plesmanlaan 121, 1066 CX Amsterdam, the Netherlands., Klarenbeek S; Experimental Animal Pathology, the Netherlands Cancer Institute, Plesmanlaan 121, 1066 CX Amsterdam, the Netherlands., Altelaar M; Proteomics Core Facility, the Netherlands Cancer Institute, Plesmanlaan 121, 1066 CX Amsterdam, the Netherlands; Biomolecular Mass Spectrometry and Proteomics, Bijvoet Center for Biomolecular Research and Utrecht Institute for Pharmaceutical Sciences, University of Utrecht, and Netherlands Proteomics Center, Padualaan 8, 3584 CH Utrecht, the Netherlands., Peeper DS; Division of Molecular Oncology and Immunology, Oncode Institute, the Netherlands Cancer Institute, Plesmanlaan 121, 1066 CX Amsterdam, the Netherlands. Electronic address: d.peeper@nki.nl.
Publikováno v:
Cell reports. Medicine [Cell Rep Med] 2022 Jun 21; Vol. 3 (6), pp. 100655. Date of Electronic Publication: 2022 Jun 09.
Autor:
Rozeman EA; Department of Medical Oncology, Netherlands Cancer Institute, Amsterdam, the Netherlands., Hoefsmit EP; Department of Molecular Oncology and Immunology, Netherlands Cancer Institute, Amsterdam, the Netherlands., Reijers ILM; Department of Medical Oncology, Netherlands Cancer Institute, Amsterdam, the Netherlands., Saw RPM; Melanoma Institute Australia, The University of Sydney, Sydney, New South Wales, Australia.; Department of Surgery, Mater Hospital, Sydney, New South Wales, Australia.; Department of Surgery, Royal Prince Alfred Hospital, Sydney, New South Wales, Australia., Versluis JM; Department of Medical Oncology, Netherlands Cancer Institute, Amsterdam, the Netherlands., Krijgsman O; Department of Molecular Oncology and Immunology, Netherlands Cancer Institute, Amsterdam, the Netherlands.; Oncode Institute, Utrecht, the Netherlands., Dimitriadis P; Department of Molecular Oncology and Immunology, Netherlands Cancer Institute, Amsterdam, the Netherlands., Sikorska K; Department of Biometrics, Netherlands Cancer Institute, Amsterdam, the Netherlands., van de Wiel BA; Department of Pathology, Netherlands Cancer Institute, Amsterdam, the Netherlands., Eriksson H; Department of Oncology and Pathology, Karolinska Institutet, Stockholm, Sweden.; Department of Oncology/Skin Cancer Center, Theme Cancer, Karolinska University Hospital, Stockholm, Sweden., Gonzalez M; Melanoma Institute Australia, The University of Sydney, Sydney, New South Wales, Australia., Torres Acosta A; Department of Biometrics, Netherlands Cancer Institute, Amsterdam, the Netherlands., Grijpink-Ongering LG; Department of Biometrics, Netherlands Cancer Institute, Amsterdam, the Netherlands., Shannon K; Melanoma Institute Australia, The University of Sydney, Sydney, New South Wales, Australia.; Department of Surgery, Royal Prince Alfred Hospital, Sydney, New South Wales, Australia., Haanen JBAG; Department of Medical Oncology, Netherlands Cancer Institute, Amsterdam, the Netherlands.; Department of Molecular Oncology and Immunology, Netherlands Cancer Institute, Amsterdam, the Netherlands., Stretch J; Melanoma Institute Australia, The University of Sydney, Sydney, New South Wales, Australia.; Department of Surgery, Mater Hospital, Sydney, New South Wales, Australia.; Department of Surgery, Royal Prince Alfred Hospital, Sydney, New South Wales, Australia., Ch'ng S; Melanoma Institute Australia, The University of Sydney, Sydney, New South Wales, Australia.; Department of Surgery, Mater Hospital, Sydney, New South Wales, Australia.; Department of Surgery, Royal Prince Alfred Hospital, Sydney, New South Wales, Australia., Nieweg OE; Melanoma Institute Australia, The University of Sydney, Sydney, New South Wales, Australia.; Department of Surgery, Mater Hospital, Sydney, New South Wales, Australia.; Department of Surgery, Royal Prince Alfred Hospital, Sydney, New South Wales, Australia., Mallo HA; Department of Medical Oncology, Netherlands Cancer Institute, Amsterdam, the Netherlands., Adriaansz S; Department of Medical Oncology, Netherlands Cancer Institute, Amsterdam, the Netherlands., Kerkhoven RM; Genomics Core Facility, Netherlands Cancer Institute, Amsterdam, the Netherlands., Cornelissen S; Core Facility Molecular Pathology and Biobanking, Netherlands Cancer Institute, Amsterdam, the Netherlands., Broeks A; Core Facility Molecular Pathology and Biobanking, Netherlands Cancer Institute, Amsterdam, the Netherlands., Klop WMC; Department of Surgical Oncology, Netherlands Cancer Institute, Amsterdam, the Netherlands., Zuur CL; Department of Surgical Oncology, Netherlands Cancer Institute, Amsterdam, the Netherlands., van Houdt WJ; Department of Surgical Oncology, Netherlands Cancer Institute, Amsterdam, the Netherlands., Peeper DS; Department of Molecular Oncology and Immunology, Netherlands Cancer Institute, Amsterdam, the Netherlands.; Oncode Institute, Utrecht, the Netherlands., Spillane AJ; Melanoma Institute Australia, The University of Sydney, Sydney, New South Wales, Australia.; Department of Surgery, Mater Hospital, Sydney, New South Wales, Australia.; Breast and Melanoma Surgery Unit, Royal North Shore hospital, Sydney, New South Wales, Australia., van Akkooi ACJ; Department of Surgical Oncology, Netherlands Cancer Institute, Amsterdam, the Netherlands., Scolyer RA; Melanoma Institute Australia, The University of Sydney, Sydney, New South Wales, Australia.; Department of Tissue Pathology and Diagnostic Oncology, Royal Prince Alfred Hospital and New South Wales Health Pathology, Sydney, New South Wales, Australia., Schumacher TNM; Department of Molecular Oncology and Immunology, Netherlands Cancer Institute, Amsterdam, the Netherlands.; Oncode Institute, Utrecht, the Netherlands., Menzies AM; Melanoma Institute Australia, The University of Sydney, Sydney, New South Wales, Australia.; Department of Medical Oncology, Royal North Shore and Mater Hospitals, Sydney, New South Wales, Australia., Long GV; Melanoma Institute Australia, The University of Sydney, Sydney, New South Wales, Australia.; Department of Medical Oncology, Royal North Shore and Mater Hospitals, Sydney, New South Wales, Australia., Blank CU; Department of Medical Oncology, Netherlands Cancer Institute, Amsterdam, the Netherlands. c.blank@nki.nl.; Department of Molecular Oncology and Immunology, Netherlands Cancer Institute, Amsterdam, the Netherlands. c.blank@nki.nl.
Publikováno v:
Nature medicine [Nat Med] 2021 Feb; Vol. 27 (2), pp. 256-263. Date of Electronic Publication: 2021 Feb 08.
Autor:
Hoefsmit EP; Molecular Oncology & Immunology, Netherlands Cancer Institute, Amsterdam, The Netherlands., Rozeman EA; Medical Oncology, Netherlands Cancer Institute, Amsterdam, The Netherlands., Van TM; Molecular Oncology & Immunology, Netherlands Cancer Institute, Amsterdam, The Netherlands., Dimitriadis P; Molecular Oncology & Immunology, Netherlands Cancer Institute, Amsterdam, The Netherlands., Krijgsman O; Molecular Oncology & Immunology, Netherlands Cancer Institute, Amsterdam, The Netherlands., Conway JW; Melanoma Institute Australia, North Sydney, New South Wales, Australia., Pires da Silva I; Melanoma Institute Australia, North Sydney, New South Wales, Australia., van der Wal JE; Department of Pathology, Netherlands Cancer Institute, Amsterdam, The Netherlands., Ketelaars SLC; Molecular Oncology & Immunology, Netherlands Cancer Institute, Amsterdam, The Netherlands., Bresser K; Molecular Oncology & Immunology, Netherlands Cancer Institute, Amsterdam, The Netherlands., Broeks A; Core Facility and Biobanking, Netherlands Cancer Institute, Amsterdam, The Netherlands., Kerkhoven RM; NKI Genomics Core Facility, Netherlands Cancer Institute, Amsterdam, The Netherlands., Reeves JW; NanoString Technologies Inc, Seattle, Washington, USA., Warren S; NanoString Technologies Inc, Seattle, Washington, USA., Kvistborg P; Molecular Oncology & Immunology, Netherlands Cancer Institute, Amsterdam, The Netherlands., Scolyer RA; Melanoma Institute Australia, North Sydney, New South Wales, Australia.; The University of Sydney Faculty of Medicine and Health, Sydney, New South Wales, Australia.; Tissue Pathology and Diagnostic Oncology, Royal Prince Alfred Hospital and New South Wales Health Pathology, Sydney, New South Wales, Australia., Kapiteijn EW; Department of Medical Oncology, Leiden University Medical Center, Leiden, The Netherlands., Peeper DS; Molecular Oncology & Immunology, Netherlands Cancer Institute, Amsterdam, The Netherlands.; Oncode Institute, Utrecht, The Netherlands., Long GV; Melanoma Institute Australia, North Sydney, New South Wales, Australia.; Royal North Shore Hospital, Melanoma Institute Australia, and The University of Sydney, Wollstonecraft, New South Wales, Australia., Schumacher TNM; Molecular Oncology & Immunology, Netherlands Cancer Institute, Amsterdam, The Netherlands.; Oncode Institute, Utrecht, The Netherlands., Blank CU; Molecular Oncology & Immunology, Netherlands Cancer Institute, Amsterdam, The Netherlands c.blank@nki.nl.; Medical Oncology, Netherlands Cancer Institute, Amsterdam, The Netherlands.
Publikováno v:
Journal for immunotherapy of cancer [J Immunother Cancer] 2020 Dec; Vol. 8 (2).